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ORIGINAL ARTICLE

Inhibition of the integrin/FAK signaling axis and c-Myc
synergistically disrupts ovarian cancer malignancy
B Xu1,2,3,10, J Lefringhouse1,2,3,4,5,10, Z Liu1,2,3,6,10, D West4,5,10, LA Baldwin1,2,3,4,5, C Ou1,2,3, L Chen1,2,3, D Napier4,5, L Chaiswing7,
LD Brewer1,2,3, D St. Clair7, O Thibault1,2,3, JR van Nagell4,5, BP Zhou1,2,3, R Drapkin8, J-A Huang6,11, ML Lu9,11, FR Ueland4,5,11 and
XH Yang1,2,3,6,11
Integrins, a family of heterodimeric receptors for extracellular matrix, are promising therapeutic targets for ovarian cancer,
particularly high-grade serous-type (HGSOC), as they drive tumor cell attachment, migration, proliferation and survival by activating
focal adhesion kinase (FAK)-dependent signaling. Owing to the potential off-target effects of FAK inhibitors, disruption of the
integrin signaling axis remains to be a challenge. Here, we tackled this barrier by screening for inhibitors being functionally
cooperative with small-molecule VS-6063, a phase II FAK inhibitor. From this screening, JQ1, a potent inhibitor of Myc oncogenic
network, emerged as the most robust collaborator. Treatment with a combination of VS-6063 and JQ1 synergistically caused an
arrest of tumor cells at the G2/M phase and a decrease in the XIAP-linked cell survival. Our subsequent mechanistic analyses
indicate that this functional cooperation was strongly associated with the concomitant disruption of activation or expression of FAK
and c-Myc as well as their downstream signaling through the PI3K/Akt pathway. In line with these observations, we detected a
strong co-ampliﬁcation or upregulation at genomic or protein level for FAK and c-Myc in a large portion of primary tumors in the
TCGA or a local HGSOC patient cohort. Taken together, our results suggest that the integrin–FAK signaling axis and c-Myc
synergistically drive cell proliferation, survival and oncogenic potential in HGSOC. As such, our study provides key genetic,
functional and signaling bases for the small-molecule-based co-targeting of these two distinct oncogenic drivers as a new line of
targeted therapy against human ovarian cancer.
Oncogenesis (2017) 5, e295; doi:10.1038/oncsis.2016.86; published online 30 January 2017

INTRODUCTION
Epithelial ovarian cancer, primarily high-grade serous-type ovarian
cancer (HGSOC), is one of the most deadly threats to women’s
health worldwide. Over 70% of HGSOC patients are diagnosed at
advanced and metastatic stages, and their 10-year survival rate is
below 30%.1,2 Also, the current treatment of ovarian cancer is
largely dependent on the limited success of chemotherapeutic
agents, such as paclitaxel and carboplatin, thereby being strongly
associated with rapid drug resistance and poor clinical outcomes.3
Hence, the improvement in treatment options, including the use
of target-based therapies, is urgently needed to combat the
malignancy of human ovarian cancer.
Integrins, a family of heterodimeric adhesion receptors for
diverse extracellular matrices, have consistently been implicated
as crucial drivers of ovarian cancer development and
progression.4,5 Clinically, a number of the RGD-based members

of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins,
are markedly elevated in aggressive ovarian tumors.6–9 These
adhesion receptors appear to promote cell adhesion, survival,
motility and invasion during ovarian tumor growth or metastatic
progression.10–13 Importantly, the functions of these integrins are
strongly dependent on the activation of focal adhesion kinase
(FAK) and its downstream signaling, including the PI3K/Akt- and
Ras/MAPK-dependent pathways.5,14,15 It is of no surprise that
inhibition of integrin function and signaling has emerged as one
of highly attractive therapeutic options for overcoming the
malignancy of human ovarian cancer.
Inhibition of the FAK-dependent signaling is one of crucial
means to disrupt the integrin-associated ovarian cancer
malignancy.14,16 As a 120 kDa intracellular non-receptor tyrosine
kinase, FAK is strongly activated, once integrins are engaged with
their extracellular matrix ligands, such as laminins, ﬁbronectin and
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Figure 1. Characterization of ovarian cancer cell sensitivity to VS-6063. (a) Differential response of cultured human low- or high-grade ovarian
cancer lines to VS-6063. Human ovarian cancer cells were grown in the presence of 5–10% fetal bovine serum, treated with indicated doses of
VS-6063 for 72 h, and assessed for cell viability with the MTT assay. (a) Highly sensitive lines: OVCAR-8, OVCAR-5 and Hey-8. (b) Moderately
sensitive lines: OVCAR-433, OVC-3 and OVC-429. (c) Resistant line: SK-OV-3. (b) Evaluation of the β1 integrin dependence of VS-6063. OVCAR-5
cells with (blue bar)or without β1 integrin stable knockdown (red bar) were treated with varying doses of VS-6063 for 72 h, followed by
analysis of viability. The extent of β1 integrin knockdown was conﬁrmed by immunoblotting (right panel). All data are representative of one of
three independent experiments. s.e. (standard errors of the means): o5% (not shown). Values: percentages of the viability of treated cells
over control—0.1% DMSO, n = 3.
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Figure 2. Identiﬁcation of JQ1 as a collaborator of VS-6063 by using chemical inhibitor-based screening. (a–c) Evaluation of the inhibitory
effect of VS-6063 or TAE-226 and candidate inhibitors on the viability of OVC-433 cells. (d) Evaluation of the potential off-target effect of JQ1
and VS-6063 combination in primary human ﬁbroblasts. The functional evaluation of inhibitors was conducted with OVC-433 cells over a
period of 72 h in the presence of 10% fetal bovine serum. The cell viability was measured by the MTT assay. Values: percentages of viable cells
over the dimethyl sulfoxide control (n = 2). All s.e.'s were o5% of the mean.
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collagens.17 Pathologically, FAK expression is markedly elevated in
a large portion of ovarian carcinomas via gene ampliﬁcation or at
protein level.16 The aberrant expression of FAK appears to be
associated with drug resistance and poor clinical outcomes in
ovarian cancer patients.18,19 Also, the integrin/FAK-dependent
signaling promotes ovarian tumor cell proliferation and survival
through diverse pathways.14,16 Knockdown or deletion of FAK
impairs tumor growth and metastatic progression of ovarian
cancer.20–23 These growing studies support FAK inhibition as a
promising avenue for mitigating ovarian cancer malignancy.
Recently, a number of small-molecule inhibitors of FAK have
displayed strong clinical application potential for ovarian cancer
malignancy.18,19,24–26 Notably, TAE-226 and VS-6063, two of most
potent inhibitors against active FAK through disruption of its Y397
residue, are highly effective in inhibiting ovarian tumor growth
and metastatic potential.20–23 Such inhibition appears to be
inversely associated with the expression of NF2/Merlin in
carcinomas cells.26–28 Despite such strong antitumor effect and
presence of promising biomarkers, the FAK inhibitors exhibit
strong off-target effects during the clinical trial.17 Thus, a better
understanding of the functional and signaling bases of these
inhibitors will be crucial for their potential application in the
clinical treatment of human ovarian cancer.
Here, we explored a strategy for enhancing the therapeutic
potential of inhibiting the integrin–FAK-dependent signaling in
ovarian cancer. By screening arrays of anti-cancer chemical
compounds, we attempted to identify the inhibitors that
were strongly cooperative with VS-6063. Also, we conducted
mechanistic analyses to unravel key molecular, signaling, genetic
and clinical bases underlying this cooperative effect. Results from
our analyses showed that JQ1, an inhibitor of the interaction
between Myc oncogenic network or their interactions with the
Bromodomain-containing transcription factors (e.g., BRD4),29,30
is the most robust collaborator of VS-6063. JQ1 and VS-6063 also
exhibited a strong synergy in the inhibition of FAK activity and
c-Myc expression, as well as their signaling through the PI3K/Akt
pathway. In addition, we detected a strong concordance in the
aberrant genetic changes or expression for FAK and c-Myc in the
primary tumors of human HGSOC. As such, our study has
identiﬁed JQ1 as a key ally of VS-6063 with respect to disruption
of oncogenic processes or signaling. Our ﬁndings support the
combination of these two inhibitors being a promising targeted
therapy for the treatment of human HGSOC.
RESULTS
Identiﬁcation of JQ1 as a robust collaborator of VS-6063 by
chemical inhibitor-based screening
As a crucial driver of ovarian cancer malignancy, the integrin–FAK
signaling axis remains a challenge regarding its therapeutic
targeting, largely because of the potential off-target effect of
FAK inhibitors.17 To overcome this clinical application barrier,
we sought to screen for a set of small-molecule inhibitors being
cooperative or synergistic to VS-6063, a phase II inhibitor of active
FAK, which is characterized by the phosphorylation at Y397
residue.28 To construct our cell viability-based screening system,
representative human HGSOC cell lines were analyzed for their
sensitivities to VS-6063. As shown in Figure 1a, OVC-8, OVC-5 and
HeyA8 lines were most sensitive to VS-6063, while OVC-429,
OVC-433 and OVC-3 lines exhibited intermediate or moderate
response. In comparison, SK-OV-3, a low-grade ovarian tumor line,
had the least sensitivity (Figure 1c), consistent with a prior study.26
Furthermore, the speciﬁc effect of VS-6063 on the integrininduced FAK activation was also validated, as OVC-5 cells
exhibited a marked decrease in the sensitivity to this inhibitor
upon the stable knockdown of β1 integrin (Figure 1b). Based on
these observations, OVC-433 line was employed as an in vitro
Oncogenesis (2017), 1 – 12

model for our subsequent screening for small-molecule inhibitors
being functionally cooperative to VS-6063.
To seek functional collaborators for the integrin–FAK signaling
axis, we evaluated the synergistic or cooperative effects of
VS-6063 with 30 potent inhibitors against diverse oncogenic
pathways in human cancer (Supplementary Table S2). Data from
these analyses revealed that JQ1, a newly identiﬁed inhibitor of
Myc oncogenic network, exhibited the most synergistic
cooperation with VS-6063 in terms of inhibiting ovarian cancer
cell viability (Figure 2a). By comparison, there was a minimal
synergy for other inhibitors of prominent oncogenic pathways,
including MK-2206 for PI3K/Akt, PD-901 for RAS/MAPK, Olaparib
for PARP involved in the DNA repairing and ICG001 for the
canonical Wnt signaling (data not shown). The functional
cooperation between VS-6063 and JQ1 also appeared to be
highly speciﬁc, as JQ1 exhibited less or minimal cooperation with
other tyrosine kinase inhibitors, such as PP2 (an inhibitor of Src
family tyrosine kinases) or Iressa/Lapatinib (inhibitor of EGFR or
ErbB2) (Figure 2b). Also, I-BET151, which is functionally similar to
JQ1,31 exhibited a strong synergy with VS-6063 (data not shown).
However, JQ1 exhibited very little synergy with TAE-226
(Figures 2b and c), an inhibitor being functionally similar to
VS-6063.25 Thus, these data support JQ1 as a strong collaborator
of VS-6063 in terms of disruption of ovarian cancer cell viability.
Moreover, we observed a minimal cooperative impact of
VS-6063 and JQ1 on the viability of normal human ﬁbroblasts
(Figure 2c), suggesting a minimal toxic or off-target effect. In line
with this notion, the synergistic or additive effect of VS-6063 and
JQ1 was detected across a panel of human HGSOC cell lines
except OVC-420 (Figure 3), regardless their differential sensitivities
to VS-6063 (Figure 1). Interestingly, our extensive analyses showed
that low doses of JQ1 (0.1–1.6 μM) appeared sufﬁcient to enhance
the inhibitory effect of VS-6063 in multiple ovarian cancer cell lines
(Figure 3), implicating a strong catalyst-like role of JQ1. Taken
together, these observations indicate that JQ1 likely acts as a
catalyst for the inhibitory effect of VS-6063 on the FAK-driven cell
viability in ovarian cancer.
Scope of functional cooperation of VS-6063 and JQ1
We further investigated if the functional cooperation of VS-6063
and JQ1 in ovarian cancer extended beyond cell viability. Our
analyses showed that the combination of VS-6063 and JQ1 led to
a signiﬁcant decrease in the portion of cells entering into the
S phase, but an increase in cell arrest at G2/M in all three cancer
cell lines (OVC-429, OVC-8 and OVC-433), compared with the use
of individual inhibitors alone (Figure 4). Furthermore, a synergistic
or additive effect of this inhibitor combination was detected
regarding the survival of VS-6063-sensitive OVC-8 cells, but not
SK-OV-3 cells (Figures 5a and b). Interestingly, JQ1 at the dose
range of 0.3–0.6 μM also exhibited a strong synergy with
VS-6063 in induction of cell apoptosis, as reﬂected by an increased
cleavage of PARP proteins in SK-OV-3 cells, but not in OVC-8 cells
(Figure 5c). In line with these observations, we detected a strong
synergy of VS-6063 and JQ1 with respect to the disruption of cell
morphologies (Supplementary Figure S1). These observations
implicated a broad functional collaboration for VS-6063 and JQ1
in ovarian cancer, particularly regarding cell proliferation and
survival.
Molecular and signaling bases of functional cooperation between
VS-6063 and JQ1
Next, we attempted to delineate the molecular and signaling
bases underlying the functional cooperation of VS-6063 and JQ1
in ovarian cancer. We noted that expression of FAK and c-Myc,
which are regarded as key targets of VS-6063 and JQ1,
respectively,28,30 varied among the cultured HGSOC cell lines
(Figure 6a). In particular, the VS-6063-resistant SK-OV-3 line had
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Figure 3. Deﬁning the scope of the effectiveness of VS-6063 and JQ1 combination. A total of six different HGSOC cell lines (OVC-8, Hey-8, OVC-3,
OVC-5, OVC-420 and OVC-429) and one low-grade (SK-OV-3) cell lines were treated with indicated inhibitors for 72hrs, followed by analysis of cell
viability with MTT assay. Values: percentages of viable cells over the dimethyl sulfoxide control (n = 2). All s.e.'s were o5% of the mean.

low expression of active or total FAK or c-Myc. (Figures 1a and 6a).
By comparison, there was a lack of an apparent association for
BRD4, another key target of JQ1 (data not shown). Interestingly,
the varying expression of FAK and c-Myc in ovarian cancer cell
lines appeared to be closely correlated with their responses to the
treatment of these two inhibitors. Notably, both OVC-8 and
OVC-433 lines displayed a dose-dependent decrease in the
phosphorylation of FAK or c-Myc protein upon the treatment
with VS-6063 or JQ1 or combination (Figures 6a and b). Consistent
with these observations, c-Myc knockdown decreased tumor cell
sensitivity to the VS-6063 treatment (Figure 6c). Together, our data
illustrate that ovarian tumor cell response to the treatment of
VS-6063 and c-Myc is strongly dependent on the activation or
expression of FAK and c-Myc.
The strong cooperative effect of VS-6063 and JQ1 on the
activation of FAK and/or Myc was further reﬂected by a
corresponding decrease in their signaling through the PI3K/Akt
in OVC-8 and OVC-433 lines (Figure 6d). In comparison, there was
a limited or minimal difference in the Ras/MAPK pathway.
Furthermore, our analyses showed that these two inhibitors

synergistically inhibited the survival of ovarian tumor cells via
activation of the Caspase 8/XIAP-dependent pathway (Figure 6e).
However, such inhibitor combination appeared to have a minimal
impact on the activation of the PI3K/Akt or Erk1/2 pathway in
VS-6063-resistant SK-OV-3 line. Taken together, our results
demonstrate that the synergistic role of VS-6063 and JQ1 in
ovarian cancer is attributed to their impact on the activation of
FAK and c-Myc, as well as their downstream signaling.
Genetic bases for the simultaneous disruption of FAK and c-Myc
Our further analyses provided genetic support for the co-targeting
of the integrin–FAK signaling pathway and Myc oncogenic
network in ovarian cancer. It is known that both FAK and Myc
are closely located at 8q24 locus, one of the most ampliﬁed
regions in ovarian tumor genomes.32 Thus, it was of no surprise
that FAK and c-Myc exhibited extensive co-ampliﬁcation in HGSOC
primary tumors in the TCGA patient cohort (Figure 7a). Such
co-ampliﬁcation appeared to be independent of tumor subtypes.
By comparison, FAK displayed a minimal co-ampliﬁcation with
Oncogenesis (2017), 1 – 12
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carboplatin-resistant OV-90 cells (Figures 1 and 8). Together, these
data indicate the effectiveness of VS-6063 and JQ1 combination in
ovarian cancer likely goes beyond tumor chemoresistance.
Since activation of the integrin–FAK signaling axis is frequently
upregulated in the tumor cells conferring the epithelial–mesenchymal transition (EMT) phenotype,17 we examined the role of
VS-6063 and JQ1 combination in the EMT-associated chemoresistance. As shown in Figure 8c, the EMT variant of OVC-5 line
exhibited more resistance to the treatment of VS-6063 and JQ1
combination, compared with their counterparts (po 0.05). Conversely, the forced expression of E-cadherin reversed this effect
(po 0.05). These observations indicate that treatment with
VS-6063 and JQ1 combination is effective in impairing the EMTassociated tumor cell viability in ovarian cancer.

Figure 4. Effect of VS-6063 and JQ1 combination on cell cycle
progression. OVC-8 (a), OVC-429 (b) and OVCAR-433 (c) cells were
cultured in the presence of dimethyl sulfoxide or inhibitors for 48 h
and followed by analyses of PI staining on ﬂow cytometry. Values:
percentage of cells at the cell phases indicated (mean ± s.e., n = 3).
Data was representative of three independent experiments.

N-Myc or BRD4 (data not shown), which are also implicated as
crucial targets of JQ1.30 In addition, we observed a strong
co-upregulation of FAK and c-Myc in the primary tumors of a local
HGSOC patient cohort (P o 0.03) (Figure 7b). Together, these
results unveil genetic and clinical bases underlying simultaneous
alterations in FAK and c-Myc in ovarian cancer.
Modulation of tumor cell sensitivity to chemotherapeutic agents
by VS-6063 and JQ1
Based on the studies of the integrin–FAK signaling axis,19,33 we
also evaluated the effect of the VS-6063 and JQ1 combination on
the chemoresistance of ovarian cancer. Our data showed that
in multiple ovarian cancer cell lines, treatment with a low
concentration of VS-6063 alone actually led to more resistance
to paclitaxel in ovarian cancer cells (Figure 8a). In contrast,
treatment with VS-6063 and JQ1 combination appeared to be
equally effective in the inhibition of viability of parent and
Oncogenesis (2017), 1 – 12

DISCUSSION
While the integrin–FAK signaling axis and Myc oncogenic network
are both implicated in promoting HGSOC tumor development and
progression,17,30,34 a simultaneous targeting of these two key
drivers has rarely been considered as a targeted therapy for the
treatment of such deadly disease. Here, we reported a strong
synergy between JQ1, a newly identiﬁed potent inhibitor of Myc
oncogenic network, and VS-6063, a small molecule blocking the
activation of integrin-mediated FAK, in terms of the inhibition of
ovarian tumor cell proliferation and survival. Our data also reveal
that the functional cooperation of VS-6063 and JQ1 is linked to
their impact on the action of FAK (phosphorylated at Y397 residue)
and Myc, as well as their signaling through the PI3K/Akt pathway.
In line with such observation, the siRNA-mediated Myc downregulation impairs ovarian tumor cell sensitivity to VS-6063.
Treatment with a combination of VS-6063 and JQ1 also effectively
decreases intrinsic or the EMT-associated chemoresistance of
ovarian cancer cells. Clinically, Myc and FAK appear to be coampliﬁed or co-upregulated at the genomic or protein level in the
primary tumors of human HGSOC. Thus, our study provides strong
molecular, cellular and genetic bases for the co-targeting of the
integrin–FAK signaling axis and Myc to mitigate ovarian cancer
malignancy.
Our study suggests that the synergistic or cooperative effect of
VS-6063 and JQ1 is largely attributed to the inhibition of ovarian
cancer cell survival (Figures 4 and 5). Mechanistically, this appears
to be linked to the effect on the XIAP/Bim-mediated and caspase
8-dependent apoptosis (Figure 6a). While Bim is long recognized
for its antagonizing role in the integrin-mediated tumor cell
survival,35 it is strongly induced by JQ1, according to recent
studies.36 Thus, VS-6063 and JQ1 may synergistically inhibit
ovarian tumor cell survival largely by mitigating the integrin–
FAK-dependent cell survival or activation of the Bim/caspase
8-linked apoptotic process. It is also worth noting that the marked
synergistic effect of VS-6063 and JQ1 on the G2/M transition of
ovarian cancer cells is consistent with the strong role of the
integrin–FAK signaling axis and the Myc oncogenic network in cell
proliferation. In fact, both VS-6063 and JQ1 are independently
implicated in suppressing tumor cell cycle in several human
cancer types.17,37 Thus, in a broad sense, the synergistic effect of
VS-6063 and JQ1 on ovarian cancer are largely attributed to the
combined disruption of tumor cell proliferation and survival.
One of the unexpected observations from our current study is
the synergistic effect of VS-6063 and JQ1 on the activation or
expression of FAK and c-Myc in ovarian cancer cells (Figure 6).
Accordingly, the integrin–FAK signaling axis may drive ovarian
tumorigenesis through affecting Myc activation in a BRD4independent manner.30 However, such functional link may also
be associated with a potential translational activation of c-Myc by
FAK.38 In this regard, it is of no surprise that FAK is not present in
the list of candidate kinase drivers obtained from a large-scale
shRNA-mediated functional screening in ovarian cancer cells.30
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Figure 5. Effect of VS-6063 and JQ1 on ovarian tumor cell survival. (a, b) Flow cytometry-based analyses of Annexin V and PI-positive cells in
response to treatment of VS-6063 and JQ1. OVC-8 or OVC-433 cells were treated with inhibitors over 48 h, detached and stained with
propidium iodide and APC-conjugated Annexin V, and quantiﬁed by ﬂow cytometry (left panels). Values (right panels): Mean ± s.e., n = 3.
(c) Analyses of PARP1 cleavages in tumor cells treated with varying doses of VS-6063 and JQ1. Tumor cells were lysed in RIPA buffer, and
immunoblotted with antibody against PARP1 or β-actin (as a control).

Oncogenesis (2017), 1 – 12
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Figure 6. Identiﬁcation of the key targets and pathways of VS-6063 and JQ1 in ovarian tumor cells. (a) Expression of total or phosphorylated
FAK or Myc in human ovarian tumor cell lines. Blotting for lanes 1–8 and lanes 9–12 was conducted separately with the lysates from the
indicated human HGSOC cell lines. (b) OVC-8 or OVC-433 cell lines were treated with indicated inhibitors for 48 h, followed by analyses of
levels of total or phosphorylated FAK or Myc proteins. Equal protein loading for OVC-8 cells was also assessed by blotting β-actin shown in
Figure 5c. (c) OVC-8 cells were treated with siRNA for 24 h, and followed by incubation with 2 μm VS-6063 for additional 48 h. Tumor cells were
then analyzed by the MTT assay or blotted for c-Myc. Values (right panels): mean ± s.e., n = 3. *P-value o0.05. (d) Effect of VS-6063 and JQ1 on
key downstream pathways of the integrin–FAK signaling axis. OVC-8, OVC-433 and SK-OV-3 cells were treated with different combinations or
dosages of VS-6063 and JQ1 alone or in combination for 48 h and analyzed for the activation of the PI3k/AKT or Ras/MAPK pathway. (e) Effect
on the cell survival-related pathway. Tumor cells treated with various doses of inhibitors for 48 h and analyzed for differences in cleaved
Caspase 8, XIAP and Bim by immunoblotting. β-Actin was blotted as a control for OVC-433 or OVC-8 (shown in Figure 5c).

Meanwhile, the synergistic role of VS-6063 and JQ1 in the
inhibition of ovarian cancer cell survival or proliferation is
supported by their strong effects on the signaling through the
PI3K/Akt pathway, not on the Ras/MAPK pathway (Figure 6).
These observations are also consistent with the well-recognized
signaling or functional role of FAK or Myc across a spectrum of
human cancer.17,39 However, it is still intriguing that neither of
these pathways appears to be affected by VS-6063 or JQ1 in the
VS-6063-resistant SK-OV-3 cells (Figure 7), despite a strong effect
on cell viability. Thus, future studies will be directed to understand
how JQ1 modulates the VS-6063 resistance in ovarian cancer at
molecular levels.
Despite the high genetic variability, the majority of HGSOC cell
lines tested in the current study exhibit a robust synergistic
response to the combined treatment of VS-6063 and JQ1 (Figures
1–3). Part of such synergy appears to be associated with the
co-ampliﬁcation or co-upregulation of FAK and Myc (OVC-8,
OVC-433 and HeyA8). In contrast, the high sensitivity of OVCAR-5
cells appears to be more related to the K-Ras mutation and strong
activation of MAPK-mediated signaling (Figure 3). In fact, the
oncogenic activity of mutated K-Ras, particularly regarding its
promotion of tumor cell survival, has been shown to be strongly
dependent on the integrin–FAK signaling.40 In this regard, our
study argues that the VS-6063-resistance of SK-OV-3 cells
described in prior studies26 is likely attributed to the strong
activation of the Ras/MAPK pathway resulted from the ErbB2
ampliﬁcation (Figure 6), rather than the presence of intact
Merlin/NF2.26,28 Moreover, our data suggest that the functional
Oncogenesis (2017), 1 – 12

cooperation of VS-6063 and JQ1 is minimally affected by the
status of p53 or BRCA1/2-associated DNA repairing pathways.
Notably, OVC-420 cells are responsive to the combined inhibition
of these two inhibitors, despite of expression of intact p53. Also,
OVC-433 cells are responsive to the treatment of the VS-6063
and JQ1 combination, despite carrying deregulated BRCA1/2.41
Collectively, our study supports the notion that the treatment of
VS-6063 and JQ1 combination should be effective against human
HGSOC across a broad oncogenic spectrum.
Our current study suggests that disrupting the integrin–FAK
signaling has a limited impact on the paclitaxel resistance
of ovarian cancer, consistent with a prior study.42 Yet, this
observation differs from a recent analysis with an FAK inhibitor.19
The precise reason behind such discrepancy currently remains
unclear. Meanwhile, if our results hold, the combination of
VS-6063 and JQ1, instead of FAK inhibitor alone, should serve as
an effective target therapy to overcome the drug resistanceassociated malignancy in HGSOC. Given the dose-related toxicity
or side effect for VS-6063 or other FAK inhibitors (e.g., TAE-226),
the inclusion of JQ1-type inhibitor should lower the IC50 of FAK
inhibitors, thereby enhancing the effectiveness of VS-6063-based
targeting in ovarian cancer.
It is also worth noting that the VS-6063 and JQ1 inhibitors
may have a synergistic or cooperative effect on ovarian tumor
progression or metastasis, despite not being evaluated in the
current study. In fact, the integrin–FAK signaling axis has been
consistently linked to cell motility, invasion and colonization
during ovarian cancer metastasis.4 Also, JQ1 confers an inhibitory
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Figure 7. Gene ampliﬁcation or aberrant expression of FAK and c-MYC in human HGSOC primary tumors. (a) Co-ampliﬁcation of FAK/PTK2 and
c-Myc in HGSOC. Top panel: Differential upregulation of FAK in the primary tumors of four distinct subtypes in the TCGA cohort of HGSOC
patients. Bottom panel: Statistical evaluation of the co-ampliﬁcation of FAK and Myc in primary tumors among HGSOC subtypes from the
TCGA patient cohort. (b) Co-upregulation of FAK and c-MYC in primary tumors of local HGSOC patient cohort (n = 15). Top panel:
Representative images of FAK and Myc expression from IHC analyses of consecutive sections of primary tumors. Bottom panel: Statistical
assessment of the concordance of PTK2 and Myc upregulation. Scale bar: 100 μm.

role in tumor cell invasion.43 In line with this notion, a number of
HGSOC cell lines that confer strong invasive potential and EMT
phenotype, including OVCAR-8, OVCAR-433 and OVCAR-5,
appear to express high levels of active FAK and Myc (Figures 6
and 8). These lines are also highly susceptible to the synergistic

inhibition of VS-6063 and JQ1 in terms of tumorsphere formation
(Supplementary Figure S2). In addition, JQ1 is implicated in
suppressing the activation of Twist1, a strong driver of cell
invasion and extracellular matrix remodeling in metastatic ovarian
cancer.43,44 Collectively, the treatment with the VS-6063 and JQ1
Oncogenesis (2017), 1 – 12
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Figure 8. A link of VS-6063 and JQ1 to the drug resistance and EMT trait in ovarian cancer. (a) Effect of VS-6063 on tumor cell response to
paclitaxel in human HGSOC cell lines, including OVC-5, OVC-429 and OVC-433, as well as OVC-420 and its variant. (b) Effect of VS-6063 or JQ1
or both on tumor cell response to carboplatin in OV-90 and its carboplatin-resistant variant (OVCD), as well as OVC-433. (c) Effect of EMT on
tumor cell response to the treatment of VS-6063 and JQ1. Analyses were performed with OVC-5 parent and its E-cadherin-overexpressing
OVC-5 cells (prepared by transfection and sorting on ﬂow cytometry), along with a spontaneous EMT variant developed during cell culture.
Values: percentages of viable cells over the dimethyl sulfoxide control (n = 3). All s.e.'s were o5% of the mean. The MTT assay was conducted
after tumor cells being treated for 48 hrs (a) or 72 hrs (b, c).

combination appears to be not only effective in disrupting tumor
cell survival but also have a broad functional impact, including the
effect on tumor cell invasion or metastatic progression.
The frequent co-upregulation of FAK and c-Myc in ovarian
tumors (Figure 7) also underscores the therapeutic potential of the
VS-6063 and JQ1 combination. Since ovarian tumor cells with the
co-upregulation of FAK and Myc are more sensitive to the
combination of VS-603 and JQ1 than their counterparts (Figure 7),
the aberrant expression of FAK and Myc likely serves as promising
biomarkers for identifying the corresponding patient cohort in the
clinic. Furthermore, such patient cohort is detectable through
immunohistochemistry (IHC) or genomic analyses of patient
tumor biopsies for co-upregulation of FAK and Myc proteins. In
addition, part of such patient cohort is identiﬁable through
molecular analyses of chromosome 8q24 locus deregulation or
K-Ras mutations, according to our current study and prior
analyses.45 Consequently, the availability of potential biomarkers
and key oncogenic identities makes the combination of VS-6063
Oncogenesis (2017), 1 – 12

and JQ1 as one of highly promising target therapies for
subsequent clinical trial on HGSOC patients.
The synergistic effect of co-targeting of FAK and c-Myc detected
by the current study is also reminiscent of the synthetic lethal
therapeutic strategy described for human tumors expressing
highly level of c-Myc or being addicted to such oncogene.39,46 This
strategy is largely based on the notion that the c-Myc-driven
tumorigenesis is vulnerable to the disruption of the cyclindependent kinases.47 In the current study, we also detects a
more robust inhibition of tumor cell viability by the FAK inhibitor
in the cell lines having high level of c-Myc (OVC-8 and HreyA8) or
K-ras mutation (OVC-5) (Figures 1 and 3). Thus, part of the VS-6063
effect observed in the current study is likely attributed to its
synthetic lethal effect on ovarian cancer cells. As such, our current
study supports the FAK inhibitor alone as a targeted therapy for a
fraction of HGSOC patients with the tumors expressing high level
of c-Myc or mutated K-ras.
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In summary, our study has revealed that VS-6063 and JQ1
synergistically or cooperatively disrupt tumor cell proliferation and
survival in human HGSOC by inhibiting active FAK and c-Myc,
as well as their signaling through the PI3K/Akt pathway. The
combination of these inhibitors is selectively effective against
chemoresistant ovarian tumor cells. Importantly, FAK and Myc, are
not only co-ampliﬁed or upregulated in a large fraction of human
HGSOC tumors but also serve as strong candidate biomarkers for
identifying a corresponding patient cohort in the clinic. Consequently, the combination of VS-6063 and JQ1 is readily applied in
a clinical trial as a candidate therapy for the HGSOC patients. Our
study has therefore supported the combination of VS-6063 and
JQ1 as a new line of targeted therapy against ovarian cancer
malignancy.
MATERIALS AND METHODS
Cell lines, antibodies and chemical inhibitors
Human ovarian cancer cells lines, including HeyA8, OVCAR-3/OVC-3,
OVCAR-5/OVC-5, OVCAR-8/OVC-8, OVCAR-420/OVC-420, OVCAR-429/OVC-429, OVCAR-433/OVC-433, RMUG, IGROV and SK-OV-3 cells were obtained
from ATCC (Manassas, VA, USA), and authenticated by DNS ﬁnger print as
described in prior studies.12,48 The chemoresistant variant of OV-90 was
described in a prior study.49 All cells lines were cultured in RPMI 1604
(Invitrogen, Carlsbad, CA, USA) supplemented with 5–10% fetal bovine
serum (Sigma-Aldrich, St Louis, MO, USA) at 37 °C and 5% CO2. In addition,
normal human ﬁbroblasts were purchased from Lonza (Basel, Switzerland),
and cultured by following the protocol provided by the vendor.
The antibodies used for IHC or immunoblotting are listed in
Supplementary Table S1. The sources of small-molecule inhibitors being
screened are described in Supplementary Table S2.

adhesion plate, and cultured in the stem cell medium over 6 days, and
imaged. Sizes of tumorspheres were quantiﬁed by use of Element software
(Nikon, Melville, NY, USA).

Signaling analyses and immunoblotting
For signaling analyses, tumor cells were starved in a medium
supplemented with 0.5–1.0% fetal bovine serum overnight and followed
by culturing with growth medium (10% fetal bovine serum) in the
presence or absence of chemical inhibitors for additional 24 or 48 h. Tumor
cells were lysed in RIPA buffer plus inhibitors.51 Immunoblotting of
proteins or signaling molecules was conducted by incubating cell lysates
with indicated primary and secondary antibodies, and detecting with the
Supersignal West Pico Chemoluminescence Kit (Thermo-Fisher) The
treatment of tumor cells with inhibitors or siRNA oligos were conducted
as described in a prior study.51

IHC analyses of parafﬁn-embedded human tumor tissues
The primary ovarian tumors came from the patient cohort being recently
diagnosed or treated at the University of Kentucky-Chandler Medical
Center. IHC staining of tumor sections was conducted according to the
protocol described in a prior study.51 The parafﬁn-embedded human
HGSOC tumors were obtained through Biospecimen core at the University
of Kentucky.

Statistical analyses
All data represented the results from three independent experiments. The
statistical differences between groups were determined using a two-tailed
Student’s t-test or a two-tailed Mann–Whitney test. For IHC analyses of
human tumor tissues, Spearman’s correlation coefﬁcient was employed to
quantify correlations between Myc, total and phosphorylated FAK and
tumor stage or subtypes.

Expression of SiRNA and shRNA, and generation of stable cell line
The Myc siRNA was obtained from Cell Signaling Technology (Danvers, MA,
USA). For transfection, tumor cells were seeded in 24 wells and transfected
with siRNA oligos plus Lipofectamine 2000 (Thermo-Fisher, Waltham, MA,
USA). The transfection medium was replaced next day with fresh growth
medium. After additional 72 h of culture, cells were analyzed for cell
viability or lysed for veriﬁcation of protein knockdown by immunoblotting.
The stable knockdown of β1 integrin in OVCAR-5 cells was conducted by
viral infection with the pLKO lentiviral vector containing β1 integrin shRNA
oligo, followed by subsequent two-way cell sorting on ﬂow cytometry with
a combination of GFP and β1 integrin mAb (P5D2 clone; BioLegend, San
Diego, CA, USA), as described in our recent study.50
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